iShares Bitcoin Trust vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? iShares Bitcoin Trust trades at $46.76 (market cap $67.31B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.98 (market cap $25.27B). The key difference: iShares Bitcoin Trust is far larger — about 2.7× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while iShares Bitcoin Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 40 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| IBIT | RPRX | |
|---|---|---|
Market Cap | $67.31B | $25.27B |
Volume | 56,154,544 | 3,671,183 |
Sector | Crypto-linked | Health |
52-Week High | $68.74 | $63.96 |
52-Week Low | $33.29 | $35.44 |
Typical Hold Time | 40 Days | 1 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $46.79, down 0.89% with bearish technical signals from oscillators and mixed moving averages. Recent news highlights significant institutional inflows, including a $196 million single-day inflow on October 1, 2026. The stock faces resistance at $47-$48 with support at $44-$46, while RSI levels suggest potential oversold conditions. Financial ratios remain undisclosed in current data.
Outlook hinges on sustained institutional interest amid volatile ETF flows, with Q3 inflows reversing prior outflows. Risks include fee structures impacting returns and market sentiment shifts. Upside potential exists if Bitcoin ETF momentum continues, but investors face exposure to crypto market volatility without direct cash flow benefits.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →